Glycemic control in people with diabetes treated with cancer chemotherapy: contribution of continuous glucose monitoring

Legris, Pauline; Bouillet, Benjamin; Pâris, Justine; Pistre, Pauline; Devaux, Madeline; Bost, Stephanie; Simoneau, Isabelle; Manfrédi, Sylvain; Drouillard, Antoine; Bastie, Jean-Noel; Chaix, Marie; Massoud, Pamela; Rouland, Alexia; Aho, Serge; Boulin, Mathieu; Petit, Jean‐Michel

doi:10.1007/s00592-023-02032-z

Cited by 3 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All patients provided oral informed consent before enrolment. Full details of the ONCODIAB study have been previously reported [ 10 ].…”

Section: Methodsmentioning

confidence: 99%

Impact of a Tripartite Collaboration between Oncologist, Pharmacist and Diabetologist in the Management of Patients with Diabetes Starting Chemotherapy: The ONCODIAB Trial

Paris,

Legris,

Devaux

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

Background: Diabetes negatively impacts cancer prognosis. The objective of this work was to evaluate a tripartite oncologist–pharmacist–diabetologist collaboration in the management of patients with diabetes starting chemotherapy. Patients and Methods: The prospective ONCODIAB study (NCT04315857) included 102 adults with diabetes starting chemotherapy by whom a continuous glucose monitoring device was worn for fourteen days from the first day of the first and second chemotherapy cycles. The primary outcome was to assess pharmacist and diabetologist interventions. The secondary outcome was to evaluate the impact of the ONCODIAB follow-up on individualized patient glycemic targets at 6 months. Results: A total of 191 (2 per patient) were made either by clinical pharmacists (n = 95) or diabetologists (n = 96) during the first two chemotherapy cycles. The anatomic therapeutic chemical drug classes most frequently involved in pharmacist interventions were cardiovascular system (23%), alimentary tract and metabolism (22%), and anti-infectives for systemic use (14%). Diabetologists modified the antidiabetic treatment in 58 (62%) of patients: dose reduction (34%), drug discontinuation (28%), drug addition (24%), and dose increase (15%). Glycated hemoglobin decreased from 7.6 ± 1.7% at baseline to 7.1 ± 1.1% at 6 months (p = 0.02). Compared to individualized targets, HbA1c was higher, in the interval, or lower in 29%, 44%, and 27% of patients at baseline vs. in 8%, 70%, and 22% of patients at 6 months, respectively (p < 10−3). Conclusions: In our study, a close collaboration between oncologists, pharmacists, and diabetologists helped by continuous glucose monitoring led to overall medication optimization and better glycemic control in patients with diabetes starting chemotherapy.

show abstract

“…All patients provided oral informed consent before enrolment. Full details of the ONCODIAB study have been previously reported [ 10 ].…”

Section: Methodsmentioning

confidence: 99%

Impact of a Tripartite Collaboration between Oncologist, Pharmacist and Diabetologist in the Management of Patients with Diabetes Starting Chemotherapy: The ONCODIAB Trial

Paris,

Legris,

Devaux

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical view

Natalicchio,

Marrano,

Montagnani

et al. 2024

J Endocrinol Invest

View full text Add to dashboard Cite

Background: Increasing evidence suggests that diabetes increases the risk of developing different types of cancer. Hyperinsulinemia, hyperglycemia and chronic inflammation, characteristic of diabetes, could represent possible mechanisms involved in cancer development in diabetic patients. At the same time, cancer increases the risk of developing new-onset diabetes, mainly caused by the use of specific anticancer therapies. Of note, diabetes has been associated with a ∼10% increase in mortality for all cancers in comparison with subjects who did not have diabetes. Diabetes is associated with a worse prognosis in patients with cancer, and more recent findings suggest a key role for poor glycemic control in this regard. Nevertheless, the association between glycemic control and cancer outcomes in oncologic patients with diabetes remains unsettled and poorly debated. Purpose: The current review seeks to summarize the available evidence on the effect of glycemic control on cancer outcomes, as well as on the possibility that timely treatment of hyperglycemia and improved glycemic control in patients with cancer and diabetes may favorably affect cancer outcomes.

show abstract

Best practices and rationale for expanding Medicaid access to continuous glucose monitoring

King,

Lilly

2024

JMCP

View full text Add to dashboard Cite

Glycemic control in people with diabetes treated with cancer chemotherapy: contribution of continuous glucose monitoring

Cited by 3 publications

References 18 publications

Impact of a Tripartite Collaboration between Oncologist, Pharmacist and Diabetologist in the Management of Patients with Diabetes Starting Chemotherapy: The ONCODIAB Trial

Impact of a Tripartite Collaboration between Oncologist, Pharmacist and Diabetologist in the Management of Patients with Diabetes Starting Chemotherapy: The ONCODIAB Trial

Best practices and rationale for expanding Medicaid access to continuous glucose monitoring

Contact Info

Product

Resources

About